Efficacy of Botulinum Toxin in Temporomandibular Disorders
Launched by UNIVERSITY OF SALAMANCA · Dec 6, 2022
Trial Information
Current as of July 04, 2025
Completed
Keywords
ClinConnect Summary
TMDs are a common pathology affecting up to 70% of the population, with a maximum incidence in young patients. We used a sample of twenty patients recruited in the Maxillofacial Surgery Service of the University Hospital of Salamanca (Spain), who met the inclusion criteria, with unilateral painful symptomatology of more than three months duration. All patients were randomly treated by intramuscular and intra-articular injections of BTX (100 U) in 8 predetermined points. Pain symptomatology was assessed at the different locations, together with joint symptomatology, at baseline and 6 weeks a...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The study included patients diagnosed with TMDs, according to the established diagnostic criteria, aged between 18 and 69 years (both included) and with unilateral painful symptomatology of more than three months' duration.
- Exclusion Criteria:
- • Patients previously treated with surgery/arthrocentesis of the TMJ; patients treated in the last six months with surgery in the cervicofacial region; patients who, at the time of inclusion in the study, were being treated in a "Pain Unit" and patients who had previously received treatment with BTX.
About University Of Salamanca
The University of Salamanca, one of the oldest and most prestigious universities in Spain, is a leading institution in academic research and clinical trials. With a strong commitment to advancing healthcare and medical science, the university engages in innovative research initiatives that address critical health challenges. Its clinical trial programs are characterized by rigorous scientific methodology, interdisciplinary collaboration, and a focus on ethical standards, ensuring high-quality outcomes that contribute to the advancement of medical knowledge and patient care. The University of Salamanca fosters partnerships with healthcare professionals and industry leaders, positioning itself at the forefront of clinical research and education.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salamanca, , Spain
Patients applied
Trial Officials
JAVIER MONTERO, PROFESSOR
Study Director
Salamanca University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials